Abstract Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) have
continued to lag behind outcomes reported for children with acute lymphoblastic leukemia …

Pediatric acute myeloid leukemia (AML) develops from clonal expansion of hematopoietic
precursor cells and is characterized by morphologic and cytomolecular heterogeneity …

Simple Summary Acute myeloid leukemia in children remains a difficult disease to cure
despite intensive therapies that push the limits of tolerability. Though the intent of initial …

Children with Down syndrome (DS) are at a significantly higher risk of developing acute
myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to …

Allogeneic hematopoietic stem cell transplantation (HSCT) offers potentially curative
treatment for many children with high-risk or relapsed acute leukemia (AL), thanks to the …

Introduction: Survival rates of pediatric acute myeloid leukemia (AML) in low-and middle-
income countries (LMICs) seem extremely poor, and the available literature on the matter is …

Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …

Background Nowadays, acute leukemia (AL) among children has favorable outcome, yet
some of them get refractory or relapse mainly due to drug resistance. High-mobility group …

Despite major therapeutic improvements, children with relapsed/refractory Acute Myeloid
Leukaemia still have poor outcomes and overall survival does not exceed 40%. New …

A significant proportion of events in paediatric acute myeloid leukaemia (AML) are caused
by resistant disease (RD). We investigated clinical and biological characteristics in 66 …